"Ramipril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
Concept/Terms
Vesdil- Vesdil
- AstraZeneca Brand of Ramipril
- Promed Brand of Ramipril
Carasel- Carasel
- Almirall Brand of Ramipril
Triatec- Triatec
- Altace
- Delix
- Ramace
- Monarch Brand of Ramipril
- Zabien
- Aventis Brand of Ramipril
- Hoechst Brand of Ramipril
- Aventis Pharma Brand of Ramipril
- Astra Brand of Ramipril
- Acovil
- Tritace
Below are MeSH descriptors whose meaning is more general than "Ramipril".
Below are MeSH descriptors whose meaning is more specific than "Ramipril".
This graph shows the total number of publications written about "Ramipril" by people in Harvard Catalyst Profiles by year, and whether "Ramipril" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 0 | 2 |
| 2009 | 2 | 2 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 2 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 0 | 1 |
Below are the most recent publications written about "Ramipril" by people in Profiles.
-
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. Am J Cardiovasc Drugs. 2023 Mar; 23(2):207-217.
-
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 2022 12 06; 146(23):1749-1757.
-
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. Eur J Heart Fail. 2022 10; 24(10):1918-1927.
-
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation. 2022 10 04; 146(14):1067-1081.
-
Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 09 15; 387(11):967-977.
-
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022 01 04; 145(1):87-89.
-
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 11 11; 385(20):1845-1855.
-
Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia. 2019 08; 62(8):1319-1328.
-
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019 08; 214:77-87.
-
Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease. Hypertension. 2018 10; 72(4):986-993.